Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
35Pharma Inc
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06581159CT.gov Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pulmonary Hypertension
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hs135 (this asset) | 35Pharma Inc | P1 | CC · 43 |
| Sildenafil | Duke University | P4 | BB |
| Epoprostenol | National Center for Research Resources (NCRR) | P4 | BB |
| Tadalafil | Ochsner Health System | P4 | B |
| Uniprost | University of California, San Diego | P3 | B |
| ut-15 | United Therapeutics | P3 | B |
| Bosentan | Royal Brompton & Harefield NHS Foundation Trust | P4 | B |
| Iloprost | Actelion | P2 | B |
| Bardoxolone Methyl Ester | Biogen | P2 | B |
+20 more in the Pulmonary Hypertension cohort
Other indications for hs135
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diastolic Heart Failure | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hs135 in Pulmonary Hypertension. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hs135-pulmonary-hypertension
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →